Skip to content
akaturk Academic measurement
Sign in Sign up

OpenAlex topic

Melanoma and MAPK Pathways

This page lists works and academicians tagged with an OpenAlex topic. It is not a YÖKSİS primary or secondary field.

OpenAlex 844 works 12 author topics

Works

844 works

  1. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas 2015
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.7%

    No abstract yet.

  2. Correlation between Sustained c Jun N terminal Protein Kinase Activation and Apoptosis Induced by Tumor Necrosis Factor alpha in Rat Mesangial Cells 1998
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 99.0%

    Rat mesangial cells are normally resistant to tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis. In this report we show that the cells can be made susceptible to the apoptotic effect of TNF-alpha when pretreated with actinomycin D, cycloheximide, or vanadate. c-Jun N-terminal protein kinase (JNK) has been thou…

  3. Ras pathway activation in hepatocellular carcinoma and anti tumoral effect of combined sorafenib and rapamycin in vivo 2009
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 99.0%

    No abstract yet.

  4. GTP-Dependent K-Ras Dimerization 2015
    OpenAlex top 1% OpenAlex 99.0%

    No abstract yet.

  5. Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301 2023
    OpenAlex top 1% OpenAlex 99.7%

    PURPOSE Lazertinib is a potent, CNS-penetrant, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This global, phase III study (LASER301) compared lazertinib versus gefitinib in treatment-naïve patients with EGFR-mutated (exon 19 deletion [ex19del]/L858R) locally advanced or metastatic…

  6. Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer 2020
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 96.9%

    No abstract yet.

  7. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial 2023
    OpenAlex top 1% OpenAlex 99.1%

    No abstract yet.

  8. Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pediatric Low-Grade Gliomas 2011
    OpenAlex top 10% OpenAlex 93.6%

    No abstract yet.

  9. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection 2007
    OpenAlex top 10% OpenAlex 97.2%

    BACKGROUND: Sentinel lymph node (SLN) positivity has been found to be strongly associated with a poor prognosis in melanoma. OBJECTIVES: This large referral centre study was conducted: (i) to confirm the powerful prognostic value of SLN biopsy (SLNB); (ii) to correlate patient prognosis to the micromorphometric featur…

  10. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA 2024
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.8%

    BACKGROUND: Amivantamab-lazertinib significantly prolonged progression-free survival (PFS) versus osimertinib in patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small-cell lung cancer [NSCLC; hazard ratio (HR) 0.70; P < 0.001], including those with a history of brain metastases (HR 0.69). Pat…

  11. c-Jun N-Terminal Kinase 2 Deficiency Protects Against Hypercholesterolemia-Induced Endothelial Dysfunction and Oxidative Stress 2008
    OpenAlex top 10% OpenAlex 90.9%

    BACKGROUND: Hypercholesterolemia-induced endothelial dysfunction due to excessive production of reactive oxygen species is a major trigger of atherogenesis. The c-Jun-N-terminal kinases (JNKs) are activated by oxidative stress and play a key role in atherogenesis and inflammation. We investigated whether JNK2 deletion…

  12. SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers 2019
    OpenAlex top 10% OpenAlex 93.2%

    Targeted inhibition of the ERK-MAPK pathway, upregulated in a majority of human cancers, has been hindered in the clinic by drug resistance and toxicity. The MRAS-SHOC2-PP1 (SHOC2 phosphatase) complex plays a key role in RAF-ERK pathway activation by dephosphorylating a critical inhibitory site on RAF kinases. Here we…

Academicians

12 academicians